ISSN: 1538-7933

Journal Home

Journal Guideline

Journal of Thrombosis and Haemostasis Q1 Unclaimed

Wiley-Blackwell Publishing Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Journal of Thrombosis and Haemostasis is a journal indexed in SJR in Medicine (miscellaneous) and Hematology with an H index of 204. It has a price of 2600 €. It has an SJR impact factor of 3,086 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 3,086.

Journal of Thrombosis and Haemostasis focuses its scope in these topics and keywords: venous, pulmonary, patients, review, systematic, management, embolism, risk, bleeding, clinical, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Hematology (Q1) Medicine (miscellaneous) (Q1)

Price

2600 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

3,086

SJR Impact factor

204

H Index

358

Total Docs (Last Year)

1109

Total Docs (3 years)

12603

Total Refs

8687

Total Cites (3 years)

841

Citable Docs (3 years)

9.11

Cites/Doc (2 years)

35.2

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Annual Review of Public Health Q1
Annual Review of Pathology: Mechanisms of Disease Q1
The Lancet Global Health Q1
Annual Review of Clinical Psychology Q1
JAMA - Journal of the American Medical Association Q1

Compare this journals

Aims and Scope

Best articles by citations

Factor XIII in bronchoalveolar lavage fluid from children with chronic bronchoalveolar inflammation

Prevalence of inherited bleeding disorders in cases of idiopathic menorrhagia: a case of five blind men describing an elephant

Pathogenic antibodies to coagulation factors. Part II. Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor

FORUM

Fibrinogen as predictor of ischemic stroke in patients with non-valvular atrial fibrillation

An association analysis between genetic polymorphisms of matrix metalloproteinase-3 and methylenetetrahydrofolate reductase and myocardial infarction in Japanese

A different view of 'Toc', as I knew him

Antibodies to tissue factor pathway inhibitor are uncommonly detected in patients with infection-related antiphospholipid antibodies

Temporary inferior vena caval filter use in pregnancy

Influence of membrane-bound tumor necrosis factor (TNF)-alpha on obesity and glucose metabolism

Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? No

Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes

SHOW MORE ARTICLES

The plasma hemostatic proteome: thrombin generation in healthy individuals

Cdc42-dependent F-actin dynamics drive structuration of the demarcation membrane system in megakaryocytes

Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound1

Salvianolic acid A inhibits platelet activation and arterial thrombosis via inhibition of phosphoinositide 3-kinase

Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No

The benefits of excess EPCR

Revisited role of microparticles in arterial and venous thrombosis

Lack of secondary microthrombosis after thrombin-induced stroke in mice and non-human primates

An informed consent form for treatment with oral anticoagulants

Lupus anticoagulants and anticardiolipin antibodies: personal reminiscences, a little history, and some random thoughts

More on: intensive factor VIII exposure and inhibitor development in mild hemophilia A

Platelet-derived sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2